Secrecy shrouds taxpayer-supported research [New Jersey]
By North Jersey Media Group,
North Jersey Media Group
| 06. 19. 2005
The church organist filled out a disclosure form.
So did the part-time bartender.
Both were required to disclose any jobs other than their positions with Rowan University, a state school.
Dr. Raphael Mannino, too, has employment beyond his public-sector position as an associate professor at the University of Medicine and Dentistry of New Jersey. He's an executive with one biotech start-up company and a paid board member of another.
But there's no disclosure form on file for him with the state Executive Commission on Ethical Standards. And there are none on file for anyone else at UMDNJ, or at either of the state's two other research universities.
Mannino is just one example of a hole in the system that ensures public interests, not private ones, are served by those involved in taxpayer-supported medical research.
Secrecy is important to the biotech industry, in both its business and research incarnations. After all, this is a world where the sole ownership of ideas is the basis of profits.
The picture is more complicated on the public side of the biotechnology partnership.
In particular...
Related Articles
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
By Adam Zewe, MIT News | 02.07.2024
A tiny device built by scientists at MIT and the Singapore-MIT Alliance for Research and Technology could be used to improve the safety and effectiveness of cell therapy treatments for patients suffering from spinal cord injuries.
In cell therapy, clinicians...